The results of ZeNix, a Phase 3 clinical trial that took place in 11 sites across Georgia, Moldova, Russia, and South Africa, revealed that the BPaL treatment remains effective against highly drug-resistant strains of tuberculosis (TB) with reduced dosage and/or duration of the linezolid component of the regimen.1 Along with the maintenance of efficacy, there was a decrease in linezolid-associated side effects that accompanied the reduced dosage or duration of linezolid.1 The results from the trial, which was led by TB Alliance, a non-profit TB drug developer, were published today in the New England Journal of Medicine. Read more here.
top of page
Recent Posts
See AllThis report marks the midway point of the 1/4/6×24 Campaign, which calls for the universal implementation of the best available TB regimens — as little as one month or once weekly for TB prevention, f
20
Their annual review provides an overview of research and development of innovations for diagnosing, preventing, treating, and curing HIV, hepatitis C virus (HCV), and tuberculosis (TB). View the full
30
The Indonesia AIDS Coalition (IAC) and Indonesia for Global Justice (IGJ) have filed a patent opposition for the Tuberculosis (TB) drug Bedaquiline with dispersible tablet formulations (hereinafter, i
380
bottom of page